Sunday, November 19, 2017
Tailwinds' Take: with recent approvals from Kite and Novartis, along with 20 Phase III drug partnerships, Cryoport is poised to have explosive revenue growth over the next few years. As they say, "Tip of the iceberg." IRVINE, Calif., Nov. 2, 2017 /PRNewswire/...
IRVINE, Calif., Oct. 26, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"), the world's leading cold chain logistics company serving the life sciences industry, today announced the launch of a new website supporting its CryoStork(SM) cryogenic logistics solutions...
Tailwinds' Take: CYRX holds a commanding position in the delivery of regenerative therapeutics. KITE's drug will be the second approved in this space. Expect more approvals and more Cryoport engagements going forward.  IRVINE, Calif., Sept. 5, 2017 /PRNewswire/ -- Cryoport (NASDAQ: CYRX, CYRXW)...
Tailwinds' Take: CYRX is in a sweet spot and will be for at least the next couple of years as they will continue to gain market share and revenue growth is set to go hyperbolic. The stock will likely...
Tailwinds' Take: This announcement was well anticipated, but great news nonetheless. Revenue guidance of $8-10M per annum from this contract is double trailing 12 month revenues, so the upside is huge. Expect to see Kite contract announced in not...
Since we bought CYRX, the stock has gone up close to 200%. In the process, it has become by far the largest position in the Tailwinds Select Portfolio. Normally, this is a good thing as the winners get bigger and...
Shares of CYRX have been the best performer in the Tailwinds Select Portfolio. Since we initiated coverage on March 28, 2017, the shares have increased 133%, going from $2.09 to last night's closing price of $4.86. With the substantial share...
IRVINE, Calif., June 19, 2017 /PRNewswire/ -- The Cryoport Biotech Activity Index (the "CoBRA IndexSM") quantifies the activity in the development and clinical trials of regenerative therapies in the United States, and acts as a means by which investors, the media...
Tailwinds' Take: CYRX's competitive strength will result in a number of partner relationships going forward as more trials move towards Phase III and commercialization.  IRVINE, Calif., June 7, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW), the world's leading cryogenic logistics...
This morning the FDA posted a note on their website that they would be having a panel review of Novartis' CAR-T therapy CTL019 (tisagenlecleucel-T) on July 12th. They will also be presenting their internal review documentation on July 10th for...
Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address